Long-term Androgen Suppression Is Superior for Prostate Cancer
(06/22/2009)
Short-term androgen suppression produces inferior survival compared with long-term androgen suppression in the treatment of locally advanced prostate cancer, according to the results of a study published in the New England Journal of Medicine.
Denosumab Provides Bone Benefits in Prostate and Breast Cancer
(06/15/2009)
Among prostate patients treated with androgen deprivation therapy, the investigational drug denosumab increases bone density and reduces the risk of fractures. Denosumab also improves bone density in breast cancer patients treated with aromatase inhibitors. These were the results of two studies presented at the 2009 annual meeting the American Society of Clinical Oncology (ASCO).
Adjuvant Radiation Therapy Improves Outcome Among Men with pT3 Prostate Cancer
(05/19/2009)
Among men treated with radical prostatectomy and found to have pT3 prostate cancer (cancer that extends beyond the prostate capsule), adjuvant treatment with radiation therapy reduces the risk of post-treatment PSA increase. The results of this Phase III clinical trial were published in the Journal of Clinical Oncology.
Statins May Reduce Risk of Prostate Cancer
(05/11/2009)
According to the results of a study presented at the annual meeting of the American Urological Association, use of the cholesterol-lowering drugs known as statins may reduce the risk of developing prostate cancer.
More Detailed Results of Provenge® in Prostate Cancer Presented
(04/29/2009)
According to the results of the Phase III IMPACT trial, treatment with Provenge® (sipuleucel-T), an investigational immunotherapy, improved overall survival by 4.1 months among men with metastatic, androgen-independent prostate cancer. These results were presented at the 2009 annual meeting of the American Urological Association.
More...
Screening/Prevention
Statins May Reduce Risk of Prostate Cancer
(05/11/2009)
According to the results of a study presented at the annual meeting of the American Urological Association, use of the cholesterol-lowering drugs known as statins may reduce the risk of developing prostate cancer.
Avodart® Reduces Prostate Cancer Risk
(04/28/2009)
Among men at increased risk of developing prostate cancer, use of Avodart® (dutasteride)—a drug currently used to treat benign prostatic hyperplasia— decreased the risk of prostate cancer by 23%. These results were presented at the 2009 annual meeting of the American Urological Association.
Questions Remain About Benefit of PSA Screening for Prostate Cancer
(04/08/2009)
Two randomized studies of prostate-specific antigen (PSA) screening for prostate cancer were recently published in the New England Journal of Medicine. One of the studies, conducted in Europe, reported that PSA screening decreased prostate cancer mortality by 20%. The other study, conducted in the United States, found that higher levels of PSA screening did not influence prostate cancer mortality.
Supplementation with Folic Acid Associated with Increased Risk of Prostate Cancer
(03/19/2009)
Supplementation with folic acid significantly increases the risk of prostate cancer, according to the results of a study recently published in the Journal of the National Cancer Institute.
PSA Screening May Lead to Overdiagnosis of Prostate Cancer
(03/13/2009)
New research indicates that PSA screening results in a long lead time (time it would take for a cancer to be diagnosed clinically in the absence of screening) and a high overdiagnosis probability (percentage of cancers detected by screening that would not have been diagnosed before death). The results of this study were published in the Journal of the National Cancer Institute.
More...
Early Stage I-II (A-B)
Denosumab Provides Bone Benefits in Prostate and Breast Cancer
(06/15/2009)
Among prostate patients treated with androgen deprivation therapy, the investigational drug denosumab increases bone density and reduces the risk of fractures. Denosumab also improves bone density in breast cancer patients treated with aromatase inhibitors. These were the results of two studies presented at the 2009 annual meeting the American Society of Clinical Oncology (ASCO).
Stress Management Before Surgery Helps Men with Prostate Cancer
(04/22/2009)
According to the results of a study published in the Journal of Clinical Oncology, men who received two sessions of stress management before undergoing radical prostatectomy for early-stage prostate cancer reported fewer mood problems before surgery and better quality of life after surgery than men who received usual care.
Prostate Cancer May Cause Men to Neglect Other Health Problems
(02/09/2009)
The majority of men with early-stage, low- to moderate-grade prostate cancer die from other causes, which indicates that they would benefit from ongoing screening and prevention for cardiovascular disease and other health conditions, according to the results of a study published in the Journal of the American Geriatric Society.
Exercise May Keep Fatigue at Bay in Men Undergoing Radiation for Prostate Cancer
(02/02/2009)
Exercise provides at least short-term relief from fatigue for men with prostate cancer who are undergoing radiation therapy—and may result in long-term improvements as well—according to the results of a study published in the Journal of Clinical Oncology.
Body Weight and C-Peptide Levels Associated with Risk of Dying from Prostate Cancer
(10/21/2008)
Excess body weight coupled with a high C-peptide level among men with prostate cancer is associated with an increased risk of death from the disease. These results were recently published in an early online version of the Lancet Oncology.
More...
Locally Advanced Stage III (C)
Long-term Androgen Suppression Is Superior for Prostate Cancer
(06/22/2009)
Short-term androgen suppression produces inferior survival compared with long-term androgen suppression in the treatment of locally advanced prostate cancer, according to the results of a study published in the New England Journal of Medicine.
Denosumab Provides Bone Benefits in Prostate and Breast Cancer
(06/15/2009)
Among prostate patients treated with androgen deprivation therapy, the investigational drug denosumab increases bone density and reduces the risk of fractures. Denosumab also improves bone density in breast cancer patients treated with aromatase inhibitors. These were the results of two studies presented at the 2009 annual meeting the American Society of Clinical Oncology (ASCO).
Adjuvant Radiation Therapy Improves Outcome Among Men with pT3 Prostate Cancer
(05/19/2009)
Among men treated with radical prostatectomy and found to have pT3 prostate cancer (cancer that extends beyond the prostate capsule), adjuvant treatment with radiation therapy reduces the risk of post-treatment PSA increase. The results of this Phase III clinical trial were published in the Journal of Clinical Oncology.
Prostate Cancer May Cause Men to Neglect Other Health Problems
(02/09/2009)
The majority of men with early-stage, low- to moderate-grade prostate cancer die from other causes, which indicates that they would benefit from ongoing screening and prevention for cardiovascular disease and other health conditions, according to the results of a study published in the Journal of the American Geriatric Society.
Neoadjuvant Taxotere® and Iressa® Well Tolerated in Men with Locally Advanced Prostate Cancer
(01/21/2009)
According to the results of a Phase II clinical trial, neoadjuvant (before surgery) treatment with Taxotere® (docetaxel) and Iressa® (gefitinib) is well tolerated in men with high-risk locally advanced prostate cancer. This study was published in the journal Cancer.
More...
Metastatic Stage IV (D)
More Detailed Results of Provenge® in Prostate Cancer Presented
(04/29/2009)
According to the results of the Phase III IMPACT trial, treatment with Provenge® (sipuleucel-T), an investigational immunotherapy, improved overall survival by 4.1 months among men with metastatic, androgen-independent prostate cancer. These results were presented at the 2009 annual meeting of the American Urological Association.
Provenge® Improves Survival Among Men with Advanced Prostate Cancer
(04/14/2009)
According to the results of a Phase III clinical trial, treatment with Provenge® (sipuleucel-T), an investigational immunotherapy, improved overall survival among men with metastatic, androgen-independent prostate cancer. This information was provided in a press release from Dendreon. More detailed results will be presented later this month at the annual meeting of the American Urological Association.
Body Weight and C-Peptide Levels Associated with Risk of Dying from Prostate Cancer
(10/21/2008)
Excess body weight coupled with a high C-peptide level among men with prostate cancer is associated with an increased risk of death from the disease. These results were recently published in an early online version of the Lancet Oncology.
September Is National Prostate Cancer Awareness Month
(08/29/2008)
As the month of September brings prostate cancer into focus, it’s a great time to increase public understanding of the disease, including its prevalence, approaches to screening and prevention, treatment options, and resources that offer updated prostate cancer information throughout the year.
Preventive Dental Care Reduces Osteonecrosis of the Jaw Associated with Bisphosphonates
(08/20/2008)
Patients who undergo preventive dental care prior to receiving therapy with bisphosphonates have a significantly reduced risk of developing osteonecrosis of the jaw. These results were published in an early online publication in the Annals of Oncology.
More...
Refactory/Recurrent
More Detailed Results of Provenge® in Prostate Cancer Presented
(04/29/2009)
According to the results of the Phase III IMPACT trial, treatment with Provenge® (sipuleucel-T), an investigational immunotherapy, improved overall survival by 4.1 months among men with metastatic, androgen-independent prostate cancer. These results were presented at the 2009 annual meeting of the American Urological Association.
Provenge® Improves Survival Among Men with Advanced Prostate Cancer
(04/14/2009)
According to the results of a Phase III clinical trial, treatment with Provenge® (sipuleucel-T), an investigational immunotherapy, improved overall survival among men with metastatic, androgen-independent prostate cancer. This information was provided in a press release from Dendreon. More detailed results will be presented later this month at the annual meeting of the American Urological Association.
Body Weight and C-Peptide Levels Associated with Risk of Dying from Prostate Cancer
(10/21/2008)
Excess body weight coupled with a high C-peptide level among men with prostate cancer is associated with an increased risk of death from the disease. These results were recently published in an early online version of the Lancet Oncology.
September Is National Prostate Cancer Awareness Month
(08/29/2008)
As the month of September brings prostate cancer into focus, it’s a great time to increase public understanding of the disease, including its prevalence, approaches to screening and prevention, treatment options, and resources that offer updated prostate cancer information throughout the year.
Preventive Dental Care Reduces Osteonecrosis of the Jaw Associated with Bisphosphonates
(08/20/2008)
Patients who undergo preventive dental care prior to receiving therapy with bisphosphonates have a significantly reduced risk of developing osteonecrosis of the jaw. These results were published in an early online publication in the Annals of Oncology.
More...